Multiple outlets report that Donald Trump announces a temporary tariff pause on generic medicines imported into the United States. Under the announced plan, generic drugs face a 0% tariff rate for a two-year period. After that two-year window, tariffs on generics are scheduled to rise substantially, with reported future rates including 100% and 200% depending on the category or timing described in the announcement. The details in the two reports align on the core structure: an initial two-year period with no tariffs, followed by much higher tariff rates later. The announcements are presented as a policy measure affecting the cost and trade conditions for generic drug imports. Both sources frame the change as a staged schedule rather than an immediate across-the-board increase. The reports do not provide additional context such as the exact definitions of the affected drug classes, implementation dates beyond the two-year period, or enforcement mechanisms.